Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Doctors say that for many patients, these medications help them get control of their obesity and other weight-related medical ...

There are precedents for a hybrid NHS-private model of healthcare. Ten years ago, a new drug treatment arrived that could ...

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. In a recent SEC filing, Metsera (MTSR) said it was ...

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...